📊 SMMT Key Takeaways
Is Summit Therapeutics Inc. (SMMT) a Good Investment?
Summit Therapeutics is a pre-revenue pharmaceutical development company with -$1.1B operating losses and -$122M annual operating cash burn. With only $106.5M in cash reserves, the company faces critical runway pressure (less than 12 months) and is entirely dependent on successful drug development or capital raises for survival. While the balance sheet shows $545.9M in equity with minimal debt, the absence of any revenue generation and unsustainable cash burn trajectory present unacceptable fundamental risks.
Summit Therapeutics Inc. Key Strengths (SMMT)
- Strong balance sheet with $545.9M stockholders' equity against only $101.9M total liabilities
- Excellent liquidity position (7.41x current ratio) with zero material long-term debt
- Minimal capital expenditure requirements ($245K) suggesting efficient asset-light R&D model
SMMT Stock Risks: Summit Therapeutics Inc. Investment Risks
- Zero revenue with no approved commercial products, indicating pre-commercialization development stage
- Critical cash runway: $106.5M in reserves against $122M annual operating burn rate (less than 1 year)
- Massive operating losses (-$1.1B) driven by R&D spend with no clear path to profitability
- Complete execution dependence on unproven drug pipeline success and regulatory approvals
- No insider buying activity (0 Form 4 filings in 90 days) suggesting lack of internal confidence
Key Metrics to Watch
- Monthly operating cash burn rate and runway extension through capital raises or revenue
- Clinical trial progress, regulatory milestones, and FDA approval timeline for pipeline candidates
- Cash balance trend and timing of first commercial revenue recognition
Summit Therapeutics Inc. (SMMT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 7.41x current ratio provides a solid financial cushion.
SMMT Profit Margin, ROE & Profitability Analysis
SMMT vs Healthcare Sector: How Summit Therapeutics Inc. Compares
How Summit Therapeutics Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Summit Therapeutics Inc. Stock Overvalued? SMMT Valuation Analysis 2026
Based on fundamental analysis, Summit Therapeutics Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Summit Therapeutics Inc. Balance Sheet: SMMT Debt, Cash & Liquidity
SMMT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Summit Therapeutics Inc.'s revenue has declined by 99% over the 5-year period, indicating business contraction. The most recent EPS of $-0.99 indicates the company is currently unprofitable.
SMMT Revenue Growth, EPS Growth & YoY Performance
SMMT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | N/A | -$21.3M | $-0.03 |
| Q3 2023 | N/A | -$21.3M | $-0.03 |
| Q2 2023 | N/A | -$14.7M | $-0.02 |
| Q1 2023 | N/A | -$21.4M | $-0.15 |
| Q3 2022 | $220.0K | -$19.6M | $-0.14 |
| Q2 2022 | $57.0K | -$16.8M | $-0.17 |
| Q1 2022 | $192.0K | -$17.5M | $-0.21 |
| Q3 2021 | $181.0K | -$17.7M | $-0.20 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Summit Therapeutics Inc. Dividends, Buybacks & Capital Allocation
SMMT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Summit Therapeutics Inc. (CIK: 0001599298)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SMMT
What is the AI rating for SMMT?
Summit Therapeutics Inc. (SMMT) has an AI grade of C with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SMMT's key strengths?
Claude: Strong balance sheet with $545.9M stockholders' equity against only $101.9M total liabilities. Excellent liquidity position (7.41x current ratio) with zero material long-term debt.
What are the risks of investing in SMMT?
Claude: Zero revenue with no approved commercial products, indicating pre-commercialization development stage. Critical cash runway: $106.5M in reserves against $122M annual operating burn rate (less than 1 year).
What is SMMT's revenue and growth?
Summit Therapeutics Inc. reported revenue of $0.0.
Does SMMT pay dividends?
Summit Therapeutics Inc. does not currently pay dividends.
Where can I find SMMT SEC filings?
Official SEC filings for Summit Therapeutics Inc. (CIK: 0001599298) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SMMT's EPS?
Summit Therapeutics Inc. has a diluted EPS of $-0.24.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is SMMT's fundamental grade?
Based on our AI fundamental analysis in June 2026, Summit Therapeutics Inc. has a C grade with 78% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is SMMT stock overvalued or undervalued?
Valuation metrics for SMMT: ROE of -34.7% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is SMMT's AI grade for 2026?
Our dual AI analysis gives Summit Therapeutics Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SMMT's free cash flow?
Summit Therapeutics Inc.'s operating cash flow is $-122.3M, with capital expenditures of $245.0K.
How does SMMT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -34.7% (avg: 15%), current ratio 7.41 (avg: 2).